Bibliography
- RAUTH AM, MELO T, MISRA V: Bioreductive therapies: an overview of drugs and their mechanisms of action. Int. J. RadiaL Oncol. Biol. Phys. (1998) 42:755–762.
- STRATFORD IJ, WORKMAN P: Bioreductive drugs into the next millennium. Anticancer Drug Des. (1998) 13:519–528.
- ••An excellent review of the future of bioreductive antitumouragents.
- JAFFAR M, STRATFORD IJ: Bioreductive drugs: selectivity towards hypoxic tissue. Exp. Opin. Ther. Patents (1999) 9:1371–1380.
- ••An excellent review of hypoxia-directed bioreductive antitu-mour agents.
- MOORE HVV: Bioactivation as a model for drug design bioreductive alkylation. Science (1977) 197:527–532.
- •A review of historical importance, one of the first studies dealing with the concept of reductive alkylation.
- FRANCK RW, TOMASZ M: The chemistry of mitomycins. In: The Chemistry of Antitumour Agents. Wilman DE (ed.), Blackie & Sons Ltd., Glasgow, Scotland (1990379–394.
- RAUTH AM, GOLDBERG Z, MISRA V: DT-diaphorase: possible roles in cancer chemotherapy and carcino-genesis. Oncol. Res. (1997) 9:339–349.
- BELINSKY M, JAISWAL AK: NAD(P)H: quinone oxidore-ductase (dt-diaphorase) expression in normal and tumor tissues. Cancer Metastasis.Rev. (1993) 12:103–117.
- MARIN A, DECERAIN AL, HAMILTON E et al.: DT-diaphorase and cytochrome B-5 reductase in human lung and breast tumours. Br. J. Cancer (1997) 76:923–929.
- LI BB, GUTIERREZ PL, AMSTAD P, BLOUGH NV: Hydroxyl radical production by mouse epidermal cell lines in the presence of quinone anti-cancer compounds. Chem. Res. Toxicol. (1999) 12:1042–1049.